Is disease activity prior to fingolimod initiation predictive of response? Fingolimod as a “common” first line treatment

In countries where fingolimod is available as first-line therapy without restrictions, we have an opportunity to observe long-term efficacy profile of this drug in treatment-naive patients according to their initial disease activity. We retrospectively analysed the data of RRMS patients treated with...

Full description

Saved in:
Bibliographic Details
Published in:Revue neurologique 2021-10, Vol.177 (8), p.935-940
Main Authors: Pantazou, V., Du Pasquier, R., Pot, C., Le Goff, G., Théaudin, M.
Format: Article
Language:English
Subjects:
Disease Modifying Treatment
Fingolimod
First Line Treatment
Highly Active
Multiple Sclerosis
Treatment Naive
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In countries where fingolimod is available as first-line therapy without restrictions, we have an opportunity to observe long-term efficacy profile of this drug in treatment-naive patients according to their initial disease activity. We retrospectively analysed the data of RRMS patients treated with FTY, focusing on 2 groups: 17 highly active patients (HA) defined as follows: ≥2 relapses in the year before treatment initiation and either≥1 Gd-enhancing T1 lesion or a significant increase in T2 lesion load from a baseline MRI; and 37 “not highly active” (NHA). We reviewed treatment efficacy (defined as NEDA-3), reasons for discontinuation and treatment tolerance in both groups. Mean follow-up duration was 48.2 months, SD 18.4. Fingolimod efficiently reduced relapses (NHA 90.3% reduction, P
ISSN:0035-3787
DOI:10.1016/j.neurol.2020.11.009